Mammary Carcinoma Case Study: Missy
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
Squamous Cell Carcinoma Case Study: Duchess
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.
Lung Carcinoma Case Study: Adley Hurwitz
After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.
Hemophagocytic Histiocytic Sarcoma Case Study: Forrest
A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.
Thyroid Carcinoma Case Study: Lulu
After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.
Splenic Hemangiosarcoma Case Study: Sam
After FidoCure® enabled treatment, Sam exceeded the 5-7 month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.
Mesothelioma Case Study: Heidi
With combination therapy that included targeted therapy guided by FidoCure® genomic sequencing, Heidi has survived over a year following her initial diagnosis of mesothelioma and is still going strong.
Telangiectatic Osteosarcoma Case Study: Scout
With a combination approach that included FidoCure® therapy, Scout has lived for 1.5 years after his initial diagnosis of telangiectatic osteosarcoma.
No Dog Left Behind: Plan of Action to Address Drug Shortages
As you are likely aware, global supply chain issues are causing shortages of crucial raw drug ingredients needed to produce targeted therapy medications. These shortages are having a significant impact on the veterinary compounding pharmacy industry, and we know that you, your patients and pet parents are feeling the effects.
We want you to know that the FidoCure® team shares your sense of urgency and we are working hard to ensure that no dog is left without the cancer treatments it needs.
Providing access to life-saving therapies is one of our core values, and we are committed to putting you and your patients first.
A Note of Thanks on World Veterinary Day: New AI Findings
As we celebrate World Veterinary Day, we would like to express our heartfelt appreciation to the entire veterinary community. We at FidoCure are proud to help serve your work and your patients with our precision medicine platform. You are the front line fighter of cancer in pets and we are honored to partner in this battle against cancer to improve the quality of life for countless dogs.
